Natera has announced that DiagCor has signed an agreement to launch Natera's Panorama non-invasive prenatal screening test, or NIPT, in Hong Kong. Panorama uses a simple blood draw from the mother to detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner's syndrome), triploidy (Triploid syndrome) and sex chromosome aneuploidies. The test, launched in the US, is highly accurate and can be performed from nine weeks onward.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110.4 USD | -3.56% |
|
-1.08% | +76.20% |
07-03 | Jerome Powell did it again | ![]() |
07-03 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... | ![]() |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.20% | 14.05B | |
+19.32% | 83.53B | |
-21.99% | 75.4B | |
+2.32% | 26.73B | |
-5.06% | 18.25B | |
+6.95% | 18.12B | |
+7.69% | 16.51B | |
+76.56% | 13.03B | |
-27.89% | 12.67B | |
+20.55% | 12.31B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- DiagCor Signs Agreement to Launch Natera's Prenatal Screening Test in Hong Kong